GeneDx Holdings (WGS) Cash & Current Investments (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash & Current Investments for 7 consecutive years, with $132.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Current Investments fell 1.49% year-over-year to $132.5 million in Q2 2026; TTM through Jun 2026 was $132.5 million, a 1.49% decrease from a year earlier, with the FY2025 full-year figure at $171.3 million, up 21.32% from the prior year.
• Cash & Current Investments was $132.5 million for Q2 2026 at GeneDx Holdings, down from $170.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $315.0 million in Q1 2022 and troughed at $106.9 million in Q2 2024.
• A 5-year average of $162.8 million and a median of $148.1 million in 2024 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 974.1% in 2022, down 69.06% in 2022.
• Over 5 years, Cash & Current Investments stood at $123.9 million in 2022, then advanced by 5.01% to $130.1 million in 2023, then rose by 8.48% to $141.2 million in 2024, then climbed by 21.32% to $171.3 million in 2025, then decreased by 22.61% to $132.5 million in 2026.
• The last three Cash & Current Investments figures came in at $132.5 million (Q2 2026), $170.7 million (Q1 2026), and $171.3 million (Q4 2025), per Business Quant data.